You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
As the circle of doctors ordering drug testing expands, labs find themselves more involved in advisory and interpretive roles that go beyond running assays.
The ongoing opioid epidemic has heightened demand among physicians for more frequent and more rapid drug testing.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
In a study, the diagnostic and delivery capsules remained in the GI tract of pigs for more than a month and transmitted wireless temperature signals.
At the ACMG meeting, Cynthia Morton said that several projects, including her team’s SEQaBOO study, are exploring the utility of genomic testing in newborn hearing screening.
A brief recap of Diagnostics news the week of Ma4r 23, 2018: Bruker, T2 Biosystems, Philips, Meridian Bioscience, Agilent, Biotechnology Industry Research Assistance Council, Becton Dickinson, Strata Oncology.